Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Categories: @vaccine-makers   

Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company has operations in pharmaceutical, animal health, and consumer care.
Website: merck.com


  • Good financial results growth rate 26.7% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (9.1%)
  • Dividend yield for the last twelve months 2.8%
  • Free cash flow yield 0.1% (LTM)
  • Share price is 61.1% higher than minimum and 11.0% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (12.2x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $0.6 mln (0.000% of cap.)

Key Financials (Download financials)

Ticker: MRK
Share price, USD:  (+2.1%)118.34
year average price 88.39  


year start price 88.05 2025-02-06

min close price 73.47 2025-05-14

max close price 118.34 2026-02-04

current price 118.34 2026-02-05
Common stocks: 2 528 810 012

Dividend Yield:  2.8%
FCF Yield LTM: 0.1%
EV / LTM EBITDA: 12.2x
EV / EBITDA annualized: 10.2x
Last revenue growth (y/y):  +3.7%
Last growth of EBITDA (y/y):  +49.7%
Historical revenue growth:  +3.0%
Historical growth of EBITDA:  +15.2%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 299 259
Net Debt ($m): 23 217
EV (Enterprise Value): 322 476
EBITDA LTM ($m): 26 386
EV / LTM EBITDA: 12.2x
Price to Book: 5.7x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2026-02-03zacks.com

MRK Q4 Earnings & Sales Beat Estimates, Stock Down on Weak '26 View

2026-02-03zacks.com

Merck (MRK) Reports Q4 Earnings: What Key Metrics Have to Say

2026-02-03proactiveinvestors.com

Merck shares dip as 2026 outlook misses Wall Street expectations

2026-02-03zacks.com

Merck (MRK) Q4 Earnings and Revenues Beat Estimates

2026-02-03wsj.com

Merck Expects Slower Earnings Growth As It Spends on Acquisitions

2026-02-03reuters.com

Merck forecasts 2026 sales below estimates on patent losses

2026-02-02247wallst.com

Merck Reports Earnings Tuesday Morning After Gaining 13% Over the Past Year

2026-01-30zacks.com

Buy, Sell or Hold MRK Stock: Key Factors to Watch Before Q4 Earnings

2026-01-29zacks.com

Why the Market Dipped But Merck (MRK) Gained Today

2026-01-28zacks.com

Merck's Non-Oncology Drugs Q4 Performance: What to Expect
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data